CM Gerrits, M Bhattacharya, S Manthena, R … - Pharmacoepidemiology and drug safety, 2007 - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 61 - Related articles - BL Direct - All 4 versions
T Mazzone, A Chait, J Plutzky - The Lancet, 2008 - Elsevier Individuals with type 2 diabetes mellitus have increased cardiovascular disease
risk compared with those without diabetes. Treatment of the residual risk, other
than blood pressure and LDL-cholesterol control, remains important as the ... Cited by 37 - Related articles - All 11 versions
HE Bays, JM Gonzlez-Campoy, GA Bray, AE … - Expert Review of Cardiovascular Therapy, 2008 - ingentaconnect.com When caloric intake exceeds caloric expenditure, the positive caloric balance
and storage of energy in adipose tissue often causes adipocyte hypertrophy and
visceral adipose tissue accumulation. These pathogenic anatomic ... Cited by 26 - Related articles - All 4 versions
CA Reasner - Journal of Cardiovascular Pharmacology, 2008 - journals.lww.com Abstract: Insulin resistance syndrome is characterized by hyper- glycemia,
atherogenic dyslipidemia, hypertension, and abdominal obesity. Hyperglycemia is
the major risk factor for microvascular complications in type 2 diabetes. ... Cited by 8 - Related articles - All 4 versions
- ►jbc.org I Pagel-Langenickel, J Bao, JJ Joseph, DR … - Journal of Biological Chemistry, 2008 - ASBMB The pathophysiology underlying mitochondrial dysfunction in insulin-resistant
skeletal muscle is incompletely characterized. To further delineate this we
investigated the interaction between insulin signaling, mitochondrial ... Cited by 9 - Related articles - All 5 versions
RA Ajjan, PJ Grant - Expert Opin. Drug Saf., 2008 - informahealthcare.com Background: Thiazolidinediones (rosiglitazone, pioglitazone) influence insulin
sensitivity and are used for the treatment of Type 2 diabetes. Rosiglitazone
achieves sustained improvements in glycaemic control, whilst having ... Cited by 6 - Related articles - All 7 versions
R Cubbon, M Kahn, MT Kearney - International journal of clinical practice, 2008 - interscience.wiley.com Patients with type 2 diabetes mellitus (T2DM) and prediabetes have a
substantially greater risk of developing cardiovascular (CV) disease than the
general population. This increased risk of CV disease is due to a complex ... Cited by 5 - Related articles - BL Direct - All 4 versions
SA Doggrell - Expert Opin. Pharmacother., 2008 - informahealthcare.com The thiazolidinediones, rosiglitazone and pioglitazone are used in the treatment
of Type 2 diabetes (T2DM). Both have been shown to decrease glycated haemoglobin
levels, fasting plasma glucose, insulin, and free fatty acids levels in ... Cited by 4 - Related articles - BL Direct - All 7 versions
RB Goldberg - Current Opinion in Endocrinology, Diabetes and …, 2007 - journals.lww.com Recent findings: The thiazolidinedione class improves endothelial vasomotion,
inhibits inflammatory and procoagulant processes and has powerful
antiproliferative and antioxidant effects. Experimentally these agents ... Cited by 4 - Related articles - BL Direct - All 4 versions
